Key clinical point: A regimen of 50 Gy given in five fractions can be used safely and effectively in real-world practice among patients with early-stage non–small cell lung cancer moderately centrally located in the chest.

Major finding: Few patients experienced grade 3 toxicity (4%), and none experienced grade 4 toxicity; median overall survival was 27.0 months, and median cancer-specific survival was 39.8 months.

Study details: A single-center prospective cohort study of 50 patients treated with 50 Gy in five fractions on alternate days for T1-2N0M0 moderately central NSCLC.

Disclosures: Dr. Rulach disclosed no conflicts of interest. The study did not receive any specific funding.